Monthly Scientific Update – July 2022 (Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures)

Kelly Butler, Dr. Reham Abdel-Wahab A recent study in Precision Oncology examined the diverse genetic and molecular profiles of biliary tract cancers (BTCs). With an eye toward therapeutic value, the study aimed to identify characteristics of each BTC subtype that confer responsiveness to targeted therapies and immunotherapies.  The researchers examined a group of 454 BTC…

Read More

Monthly Scientific Update – June 2022 (Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs. Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma)

The role of locoregional therapy in treating intrahepatic cholangiocarcinoma (iCCA) patients is still limited. Therefore, a group of researchers assessed if using a hepatic arterial infusion pump (HAIP) to deliver high-dose chemotherapy directly into the liver is similar to surgical resection. The researchers enrolled 319 patients with multifocal iCCA, including 141 patients in the HAIP…

Read More

Monthly Scientific Update – May 2022 (Ramucirumab)

Recently, a group of researchers designed a phase II, single-arm clinical trial to evaluate the use of Ramucirumab in the treatment of advanced biliary tract cancer patients. Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). The researchers enrolled patients with ECOG performance status 0-1 who were previously treated with gemcitabine-based…

Read More